First-line treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
First-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
First-line treatment
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Chemotherapy | |||||
| Chemotherapy | GOG-158 | III | Carboplatin, Cisplatin, Paclitaxel | Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. | No PFS or OS difference between cisplatin+paclitaxel and carboplatin+paclitaxel in optimally debulked stage III patients CisPt+Pac vs CarboPt+Pac: PFS: 19.4 vs 20.7 months pub 2003 |
| Chemotherapy | GOG-172 | III | Cisplatin, Paclitaxel | Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). | PFS and OS increased with IP treatment in optimally debulked stage III patients, but IP had more severe side effects CisPt+Pac (IV) vs CisPt+Pac (IP): PFS: 18.3 vs 23.8 months* pub 2006 |
| Chemotherapy | NCT00326456; MITO-2 | III | Carboplatin, Liposomal doxorubicin, Paclitaxel | Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer | No significant PFS or OS difference when paclitaxel or liposomal doxorubicin is added to carboplatin, but different toxicity profiles CarboPt+Pac vs CarboPt+PLD: PFS: 16.8 vs 19.0 months pub 2011 |
| Drugs in Clinical Development | |||||
| Chemotherapy | NCT01654146; ICON8 | III | Carboplatin, Paclitaxel | An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (ICON8) | No significantly improved PFS with weekly dose-dense chemotherapy compared to standard chemotherapy every 3 weeks SoC vs CarboPt q3w+Pac qw vs CarboPt+Pac qw: PFS: 24.5 vs 24.9 vs 25.4 months pub 2019 |
| Hormonal Therapy: Aromatase | Retrospective Study: Adjuvant Hormone Therapy in LGSC | Two sites | Letrozole, Tamoxifen, Anastrozole | Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival? | Promising PFS and OS in Low Grade Serous Cancer patients treated with letrozole, anastrozole, or tamoxifen following cytoreductive surgery PFS: Not Reached (41 months follow up) Pub 2017 |
| Hormonal Therapy: Anti-Estrogens | Retrospective Study: Adjuvant Hormone Therapy in LGSC | Two sites | Letrozole, Tamoxifen, Anastrozole | Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival? | Promising PFS and OS in Low Grade Serous Cancer patients treated with hormone therapy following cytoreductive surgery PFS: Not Reached (41 months follow up) Pub 2017 |
First-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Targeted Drugs | |||||
| Angiogenesis Inhibitors: VEGF | NCT00262847; GOG-218 | III | Bevacizumab, Carboplatin, Paclitaxel Prescribing Information | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG218) | Improved PFS, but no OS difference with addition of bevacizumab to carboplatin+paclitaxel; potential benefit for patients with stage IV disease CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac+Bev vs CarboPt+Pac: All: Stage IV patients: pub 2019 |
| Angiogenesis Inhibitors: VEGF | NCT00483782; ICON7 | III | Bevacizumab, Carboplatin, Paclitaxel Prescribing Information | ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer | Improved PFS and OS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac: All: pub 2011; 2015 |
| Angiogenesis Inhibitors: VEGF | NCT00951496; GOG-252 | III | Bevacizumab, Carboplatin, Cisplatin, Paclitaxel | A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Compared to the IV reference arm, PFS was not significantly increased with either IP regimen IV CarboPt+Pac+Bev w/ Bev maint vs IP CarboPt+Pac+Bev w/ Bev maint vs IP CisPt+Pac+Bev w/ Bev maint: PFS: 24.9 vs 27.4 vs 26.2 months pub 2019 |
| Drugs in Clinical Development | |||||
| DNA Damage Repair Pathway Inhibitors: PARP | NCT02470585; VELIA | III | Carboplatin, Paclitaxel, Veliparib | A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Veliparib added to chemotherapy and continued as maintenance significantly extended PFS in all newly diagnosed patients, but has more benefit in BRCA MUT patients CarboPt+Pac+Vel w/Vel maint vs CarboPt+Pac+Vel vs CarboPt+Pac: All patients: pub 2019 |
| Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR | IRCT2016- 022726788N1 | II | Carboplatin, Metformin, Paclitaxel | Evaluation of the clinical efficacy of adding metformin to chemotherapy regimen for patients with ovarian cancers | Improved RFS with addition of metformin to carboplatin+paclitaxel in stage I-III patients CarboPt+Pac+Met vs CarboPt+Pac: RFS: 48.0 vs 25.7 months pub 2018 |